• Source: MK-2870

MK-2870 or SKB264 is an experimental antibody–drug conjugate. The antibody component is directed against "the trophoblast cell-surface antigen 2 (TROP2), which is overexpressed in many types of solid tumors, coupled to moderate cytotoxic belotecan-derivative through a novel linker which was designed to balance the extracellular stability and intracellular rupture". The drug is developed as a partnership between Merck and the Chinese company Kelun.




References

Kata Kunci Pencarian:

• MK-2870
• List of Edison Blue Amberol Records: Popular Series
• List of minor planets: 2001–3000
• Troika card
• Meanings of minor-planet names: 2001–3000
• Internet of things
• Superfluid helium-4
• List of American open-wheel racing national champions
• List of Malaysian police officers killed in the line of duty
• Ultra-high temperature ceramic